IFNB1 and myeloid sarcoma: Surprisingly, we found no differences in the transcriptomic profile of PBMCs from patients of NTZ-group and no-NTZ group although previous reports of transcriptional changes induced by NTZ and IFN-β in MS patients have been published (68, 69).